Supplementary Figure S3 from First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas
Year: 2023
Type: supplementary-materials
Abstract: Gene signatures in baseline peripheral blood samples associated with prognosis in follicular lymphoma patients treated with rituximab and utomilumab. Higher, normalized enrichment scores (NES) correspond to poorer survival. NES were derived from gene set enrichment analysis with genes pre-ranked by hazard ratio from multivariate Cox proportional-hazards model stratified by dose levels and adjusting for age, sex, race, stage, and whether patients had progressed on prior rituximab-containing therapy. Gene sets assessed were derived from the Molecular Signatures Database (MSigDB) hallmark collection (Liberzon et al, Cell Syst 2015;1:417-25). Only significant cell populations are shown (FDR-adjusted q value <0.05).
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361889132